Table 3 Univariate analysis resluts
Group | ORR%(95% CI) | P-value | PFS months (95% CI) | P-value | OS months (95% CI) | P-value |
|---|---|---|---|---|---|---|
Age(year) | ||||||
 < 65 | 60 (44.8–75.2) | 0.168 | 9 (NA) | 0.556 | 14 (3.0–25.0) | 0.180 |
 ≥ 65 | 80 (67.6–92.4) | 12 (2.8–21.2) | 20 (NA) |  | ||
Sex | ||||||
Male | 71.4 (57.4–85.4) | 0.763 | 12 (1.4–22.6) | 0.638 | 19 (9.7–28.3) | 0.829 |
Female | 66.7 (52.1–81.3) | 9 (7.0–11.0) | 14 (3.9–24.1) |  | ||
KPS | ||||||
 < 80 | 65 (50.2–79.8) | 0.490 | 7 (2.0–12.0) | 0.124 | 13 (NA) | 0.494 |
 ≥ 80 | 75 (61.6–88.4) | 12 (6.8–17.2) | 19 (6.3–31.7) |  | ||
Primary tumour location | ||||||
Oral cavity | 61.9 (46.9–76.9) |  | 18 (NA) |  | 20 (13.5–28.5) |  |
Larynx | 75 (61.6–88.4) |  | 7 (0–14.1) |  | NA(NA) |  |
Maxillary sinusnasal cavity | 100.0 (100–100) | 0.570 | 9 (NA) | 0.930 | 14 (NA) | 0.219 |
Hypopharynx | 83.3 (71.7–94.9) |  | 7 (0–15.3) |  | NA (NA) |  |
Oropharynx | 50 (34.5–65.5) |  | 12 (NA) |  | 13 (NA) |  |
Disease status | ||||||
Local recurrence | 72.7 (58.9–86.5) | 0.506 | 9 (3.7–14.3) | 0.260 | 20 (10.9–29.1) |  |
Distant metastases | 62.5 (47.5–77.5) | 7 (0–14.3) | 13 (10.2–15.8) | 0.432 | ||
Recurrence and metastases | 100.0(100–100) | NA(NA) | NA(NA) |  | ||
No. of metastasis | ||||||
1–5 | 85.7(69.5–101.9) | 0.237 | 12 (4.5–19.5) | 0.009* | NA(NA) | 0.168 |
> 5 | 57.1(34.2–80.0) | 3 (1.9–4.1) | 12(4.5–21.2) |  | ||
PD-L1 status | ||||||
Negative | 65 (50.2–79.8) | 0.490 | 7 (1.1–12.9) | 0.059 | 19(10.5–27.5) | 0.968 |
Positive | 75 (61.6–88.4) | 12 (NA) | 20(NA) |  | ||